Antisense Therapeutics Limited (ASX:ANP) Annual Report 2020



The latest annual report of Antisense Therapeutics Limited (ANP) was published on 30 Jun 2020. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - ANP Annual Results

Amounts in AUD

Total Revenue
668.43k
Gross Profit
464.63k
EBIT
-6M
Net Tangible Assets
4.53M
Net Income
-5.91M
Capital Expenditures
-10.26k

ANP Income Statement 2020 Annual Report

As per the latest Income Statement of ANP, the Net revenue increased by $81645 (14%) compared to the previous period. The operating income in 2020 decreased by $-3.00M (-100%). The net income as per the annual report was -5.91M which decreased by $-2.96M (-101%) compared to previous year.

Income Statement Report (2020/2019)

20202019
Total Revenue668.43k586.79k
Gross Profit464.63k449.03k
Operating Income-6M-3M
Income Before Tax-5.91M-2.94M
Net Income-5.91M-2.94M

Balance Sheet - ANP 2020 Annual Report

Read further: ANP Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Antisense Therapeutics Limited showed the company increased the cash on balance sheet by $1.16M (40%). The Net tangible assets of ANP on the balance sheet were at 4.53M which is $1.72M (61%) more than previous annual report. The total stockholder equity also increased by $1.72M (61%) compared to previous reporting period.

Balance Sheet Statement Report (2020/2019)

20202019
Cash4.06M2.9M
Total Assets5.35M 3.7M
Long Term Debt--
Total Liabilities821.23k 888.84k
Total Shareholder Equity4.53M2.81M
Net Tangible Assets4.53M2.81M

Cash Flow Statement - ANP 2020 Annual Report

The 2020 annual cash flow statement of Antisense Therapeutics Limited showed that the net income decreased by $-2.96M (-101%) compared to previous reporting period. Also the capital expenditure of ANP increased by $0 (0%).

As of 2020, the total cash from investing activities was -10.26k and total cash from financing activities was 5.11M.

Cash Flow Statement Report (2020/2019)

20202019
Net Income-5.91M-2.94M
Capital Expenditures-10.26k-10.26k
Dividends Paid--
Total Cash From From Investing Activities-10.26k2.4M
Total Cash From From Financing Activities5.11M1.53M

Antisense Therapeutics Limited Annual Report History

Income Statement

Income Statement history of Antisense Therapeutics Limited (ASX:ANP)

30 Jun 202030 Jun 201930 Jun 201830 Jun 2017
Total Revenue668.43k586.79k272.42k539.37k
Cost Of Revenue203.8k137.76k210.32k202.92k
Gross Profit464.63k449.03k62.11k336.45k
Research Development1.9M1.76M1.01M1.1M
Selling General Administrative2.04M1.68M1.4M1.97M
Non Recurring----
Other Operating Expenses----
Total Operating Expenses6.67M3.58M2.62M3.29M
Operating Income-6M-3M-2.35M-2.75M
Total Other Income Expense Net89.66k51.85k16.7k-7.45k
Ebit-6M-3M-2.35M-2.75M
Interest Expense-12.54k-12.54k-12.54k-12.54k
Income Before Tax-5.91M-2.94M-2.33M-2.75M
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-5.91M-2.94M-2.33M-2.75M
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income-5.91M-2.94M-2.33M-2.75M
Net Income Applicable To Common Shares-5.91M-2.94M-2.33M-2.75M

Balance Sheet Statement

Balance Sheet Statement history of Antisense Therapeutics Limited (ASX:ANP)

30 Jun 202030 Jun 201930 Jun 201830 Jun 2017
Cash4.06M2.9M1.9M1.9M
Net Receivables689.32k606.47k331.16k427.89k
Other Current Assets256.92k--30k
Total Current Assets5.21M3.7M4.79M2.52M
Property Plant Equipment138.12k2.3k7.67k14.09k
Total Assets5.35M3.7M4.8M2.54M
Accounts Payable107.87k227.13k103.75k165.69k
Other Current Liab4.58k4.58k4.58k4.58k
Total Current Liabilities798.54k879.75k580.86k685.65k
Total Liab821.23k888.84k580.86k685.65k
Common Stock69.15M63.94M62.41M57.71M
Retained Earnings-67.04M-61.13M-58.18M-55.85M
Treasury Stock2.42M---
Other Stockholder Equity2.42M---
Total Stockholder Equity4.53M2.81M4.22M1.85M
Net Tangible Assets4.53M2.81M4.22M1.85M
Long Term Debt----

Cash Flow Statement

Cash Flow Statement history of Antisense Therapeutics Limited (ASX:ANP)

30 Jun 202030 Jun 201930 Jun 201830 Jun 2017
Net Income-5.91M-2.94M-2.33M-2.75M
Depreciation107.6k5.38k6.41k4.89k
Change To Netincome2.42M2.42M2.42M2.42M
Change To Account Receivables-339.76k-275.31k96.74k-7.6k
Change To Liabilities-259.81k218.87k-31.74k-93.81k
Change To Operating Activities34.73k67.12k-42.2k-62.91k
Total Cash From Operating Activities-3.95M-2.93M-2.3M-2.91M
Capital Expenditures-10.26k-10.26k-10.26k-15.57k
Total Cashflows From Investing Activities-10.26k2.4M-2.4M-15.57k
Net Borrowings-97.89k-97.89k-97.89k-97.89k
Other Cashflows From Financing Activities-285.15k-67.08k-344.35k31.07k
Total Cash From Financing Activities5.11M1.53M4.7M31.07k
Change In Cash1.16M1M-2.93k-2.9M
Issuance Of Stock5.49M1.6M5.04M5.04M
Dividends Paid----